Bone Biologics (BBLGW) Projected to Post Quarterly Earnings on Wednesday

Bone Biologics (NASDAQ:BBLGW) is projected to issue its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Bone Biologics Stock Up 12.5%

Shares of BBLGW opened at $35.95 on Tuesday. The company has a 50-day simple moving average of $19.49 and a 200-day simple moving average of $15.48. Bone Biologics has a 52 week low of $8.30 and a 52 week high of $35.95.

About Bone Biologics

Bone Biologics, Inc is a clinical-stage biopharmaceutical company focused on developing protein-based therapeutics designed to promote bone healing and regeneration in acute and chronic orthopedic conditions. Its proprietary platform combines key osteogenic growth factors with engineered delivery matrices to support repair in complex fractures, spinal fusion procedures and non-union bone injuries. By targeting the biology of bone formation, the company aims to overcome limitations associated with autografts, allografts and synthetic implants.

The company’s lead candidate is advancing through preclinical evaluation, with studies assessing efficacy in animal models of fracture repair and spinal arthrodesis.